{"brief_title": "Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia", "brief_summary": "This non-randomized study will test the safety and effectiveness of Genasense in patients with CLL.", "detailed_description": "This study is a two-part phase I-II study. Part 1 will determine the MTD of Genasense in patients with CLL. This dose will then be tested in a non-randomized, multi-center, Phase II sequential clinical trial of Genasense used alone for treatment of patients with advanced CLL. Pharmacokinetics of Genasense and kinetics of Bcl-2 down regulation and re-expression in CLL cells will be followed in selected patients.", "condition": "CLL", "intervention_type": "Drug", "intervention_name": "Oblimerson sodium, G3139", "criteria": "- Any age - Must have received at least one chemotherapy regimen that included fludarabine - Measurable disease - At least 3 weeks since biological therapy or radiation therapy for chronic lymphocytic leukemia - No previous stem cell transplantation - At least 3 weeks since surgery", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00021749.xml"}